volume without increasing collection time. The clinical trial to support the recent FDA clearance showed an average 10% increase in the volume of plasma collected per donation with an average collection time of less than 35 minutes.2 The Terumo BCT...
Ingredients (HPAPIs). ONFAB prides itself on high standards of customer service and manufacturing and is ISO 9001 accredited. the internationally recognized standard for an organization's internal quality management. For more information please...
of the standard of care treatment paradigm for multiple myeloma and prolongs survival for patients with this cancer type.1 Historically, depending on induction regimens and mobilization strategies, approximately 50% to 75% of patients required more...
after review of all available safety data, the Company initiated screening of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300...
Drug (IND) application for ADRX-0706 which enables the company to include China-based clinical centers in the ongoing Phase 1a/1b study for the treatment of select advanced solid tumors. ADRX-0706 is an ADC comprised of a novel fully human IgG1...
non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation. The presentation, "LEGEND: a Phase 1/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive...
a significant patient treatment milestone for the most prevalent bleeding disorder in the United States. VWD affects up to 1% of the U.S. population, including many who are undiagnosed. "The FDA orphan exclusivity is exciting news for Octapharma...
as they continue to expand their offerings under the Aurora brand. The dried flower products are available now in four 10g formats including: "This expanded offering aims to serve patients with more choice, novel cultivars and expertly grown...
or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first antibody-drug conjugate (ADC) with demonstrated...
syndrome (ACS) and percutaneous coronary intervention (PCI). Avenacy’s Eptifibatide for Injection is available as a 75 mg/100 mL single-dose vial. In line with Avenacy’s mission to champion patient safety and streamline patient care, Eptifibatide...
Cardiology at MetroHealth. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1. According to Dr. Kendra Grubb, Surgical Director of the Emory Structural Heart & Valve Center, approximately 40%† of patients with...
Livzon Pharmaceutical Group, the leading seller of PPIs in China for development and commercialization, in a deal value of $127.5 million for Greater China. Onconic Therapeutics is committed to enhancing gastrointestinal treatment and improving...
to improve the performance and outcomes of medicines with its innovative delivery systems, announced the Nature publication1 of Gennova Biopharmaceutical’s Phase 2/3 clinical trial conducted to evaluate the safety and immunogenicity of its novel...
pre-filled syringe, easy-to-use, and requires no preparation or special storage conditions. Since the product's debut in 2021, veterinary surgeons across North America, Europe, and Asia have increasingly used VETIGEL as the fastest and most...
our results in these and other areas next month at the ASGCT Annual Meeting." About Factor Bioscience Founded in 2011, Factor Bioscience develops technologies for engineering cells to promote health and improve lives. Factor Bioscience is privately...
Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health equity on a global scale. There are roughly 1 million new cancer patients each year in Africa and currently, comprehensive genomic profiling and liquid biopsy testing options...
cartilage repair as compared to traditional orthopaedic materials. The ongoing clinical trials (NCT06368700 and NCT06344481) are evaluating the safety and technical performance of the HYALEX Knee Cartilage System in symptomatic patients who require...
a therapeutic cancer vaccine across multiple tumor types, regardless of the site of origin.” ANKTIVA, a first-in-class IL-15 agonist immunotherapy for NMIBC, received Breakthrough Therapy Designation and approval from the FDA based on the safety...
focusing on the prevention and treatment of cardio, renal and metabolic diseases, announced an oral presentation on RBT-1 at the prestigious, RBT-1 (stannic protoporfin / iron sucrose) is a single dose, multi-organ, preconditioning agent that is...
our Cell Shuttle™ platform. This enables the Cellares IDMO to offer a real end-to-end solution for our customers, providing 10 times higher capacity and up to 50% lower batch price,” said Fabian Gerlinghaus, CEO of Cellares. “Our proprietary...
